[go: up one dir, main page]

DK3468998T3 - Anti-tnfrsf25-antistoffer - Google Patents

Anti-tnfrsf25-antistoffer Download PDF

Info

Publication number
DK3468998T3
DK3468998T3 DK17731434.1T DK17731434T DK3468998T3 DK 3468998 T3 DK3468998 T3 DK 3468998T3 DK 17731434 T DK17731434 T DK 17731434T DK 3468998 T3 DK3468998 T3 DK 3468998T3
Authority
DK
Denmark
Prior art keywords
antistoffer
tnfrsf25
Prior art date
Application number
DK17731434.1T
Other languages
English (en)
Inventor
Taylor H Schreiber
Jeff T Hutchins
Original Assignee
Pelican Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pelican Therapeutics Inc filed Critical Pelican Therapeutics Inc
Application granted granted Critical
Publication of DK3468998T3 publication Critical patent/DK3468998T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567Framework region [FR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75Agonist effect on antigen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK17731434.1T 2016-06-09 2017-06-09 Anti-tnfrsf25-antistoffer DK3468998T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662348009P 2016-06-09 2016-06-09
PCT/US2017/036817 WO2017214547A1 (en) 2016-06-09 2017-06-09 Anti-tnfrsf25 antibodies

Publications (1)

Publication Number Publication Date
DK3468998T3 true DK3468998T3 (en) 2022-03-07

Family

ID=59078259

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17731434.1T DK3468998T3 (en) 2016-06-09 2017-06-09 Anti-tnfrsf25-antistoffer

Country Status (15)

Country Link
US (3) US10005843B2 (da)
EP (1) EP3468998B1 (da)
JP (1) JP6961625B2 (da)
KR (1) KR102423942B1 (da)
CN (1) CN109219620B (da)
AU (1) AU2017278192A1 (da)
BR (1) BR112018075222A2 (da)
CA (1) CA3026652A1 (da)
DK (1) DK3468998T3 (da)
IL (1) IL263406B2 (da)
MX (1) MX389320B (da)
RU (1) RU2746314C2 (da)
SG (1) SG11201810853UA (da)
WO (1) WO2017214547A1 (da)
ZA (1) ZA201808317B (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104114577A (zh) 2011-09-30 2014-10-22 特瓦制药澳大利亚私人有限公司 针对TL1a的抗体及其用途
US10046047B2 (en) * 2015-02-06 2018-08-14 Heat Biologics, Inc. Vector co-expressing vaccine and costimulatory molecules
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
JP2022546023A (ja) * 2019-08-30 2022-11-02 ペリカン セラピューティクス,インコーポレイテッド Tnfrsf25抗体を用いた癌の治療方法
EP4034563A4 (en) * 2019-09-26 2023-11-08 Pelican Therapeutics, Inc. Tnfrsf25-mediated treatments of immune diseases and disorders
WO2022212668A1 (en) * 2021-03-31 2022-10-06 Heat Biologics, Inc. Methods and compositions related to tnfrsf25/dr3 agonists
JP2025515510A (ja) * 2022-06-17 2025-05-15 セレクシン インコーポレイテッド ヒトdr3に特異的に結合する抗体及びその用途
CN116514983B (zh) * 2023-06-02 2025-05-23 安徽金百奥生物科技有限公司 一种靶向dr3胞外域的纳米抗体及其应用
GB202315963D0 (en) 2023-10-18 2023-11-29 Cancer Research Tech Ltd Binding molecules
WO2025158389A1 (en) * 2024-01-24 2025-07-31 Shattuck Labs, Inc. Antibodies that bind tnfrsf25

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2204890T3 (es) 1991-03-06 2004-05-01 Merck Patent Gmbh Anticuerpos monoclonales humanizados.
AU669124B2 (en) 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
GB9125979D0 (en) 1991-12-06 1992-02-05 Wellcome Found Antibody
ZA931148B (en) 1992-02-19 1993-08-18 Schering Corp Cloning and expression of humanized monoclonal antibodies against human interfluekin-4.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5705154A (en) 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
DK1667730T3 (da) 2003-08-20 2013-09-23 Univ Miami Sammensætninger og fremgangsmåder til behandling af inflammatorisk lungesygdom
US7612179B2 (en) 2003-11-28 2009-11-03 Astrazeneca Ab antibodies binding to a C-terminal fragment of apoliopoprotein E
AU2006284922B2 (en) 2005-08-30 2012-01-19 University Of Miami Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists and immunotoxins
HUE033630T2 (en) 2006-10-02 2017-12-28 Squibb & Sons Llc CXCR4 binding human antibodies and their use
FR2907341B1 (fr) 2006-10-18 2012-08-17 Pf Medicament Utilisation d'un anticorps anti-cd151 pour le traitement du cancer
WO2010033913A1 (en) 2008-09-22 2010-03-25 Icb International, Inc. Antibodies, analogs and uses thereof
EP2462165B1 (en) * 2009-08-03 2016-05-11 University of Miami Method for in vivo expansion of t regulatory cells
WO2011106707A2 (en) * 2010-02-26 2011-09-01 Human Genome Sciences, Inc. Antibodies that specifically bind to dr3
GB201020995D0 (en) 2010-12-10 2011-01-26 Bioinvent Int Ab Biological materials and uses thereof
JP2013040160A (ja) 2011-07-01 2013-02-28 Genentech Inc 自己免疫疾患を治療するための抗cd83アゴニスト抗体の使用
JP2016504045A (ja) 2013-01-09 2016-02-12 ザ ユニバーシティー オブ マイアミThe University Of Miami TL1A−Ig融合タンパク質を用いる制御性T細胞の制御のための組成物及び方法
RU2551235C2 (ru) * 2013-08-26 2015-05-20 Илья Владимирович Духовлинов Гуманизированное моноклональное антитело, специфичное к синдекану-1
CN103592439B (zh) * 2013-09-03 2015-10-21 天津亿美诺生物科技有限公司 人尿路上皮癌特异性抗体及其应用
US9982057B2 (en) * 2014-11-17 2018-05-29 Pelican Therapeutics, Inc. Human TNFRSF25 antibody

Also Published As

Publication number Publication date
CA3026652A1 (en) 2017-12-14
SG11201810853UA (en) 2019-01-30
WO2017214547A1 (en) 2017-12-14
KR102423942B1 (ko) 2022-07-22
EP3468998A1 (en) 2019-04-17
IL263406B1 (en) 2023-05-01
JP2019526528A (ja) 2019-09-19
RU2018143977A3 (da) 2020-10-05
US10005843B2 (en) 2018-06-26
ZA201808317B (en) 2019-08-28
CN109219620A (zh) 2019-01-15
US20210017287A1 (en) 2021-01-21
BR112018075222A2 (pt) 2019-03-19
EP3468998B1 (en) 2021-12-01
JP6961625B2 (ja) 2021-11-10
KR20190015716A (ko) 2019-02-14
RU2746314C2 (ru) 2021-04-12
IL263406B2 (en) 2023-09-01
IL263406A (en) 2018-12-31
RU2018143977A (ru) 2020-07-09
US20180312599A1 (en) 2018-11-01
MX389320B (es) 2025-03-20
US20170355773A1 (en) 2017-12-14
US10683359B2 (en) 2020-06-16
CN109219620B (zh) 2023-01-31
AU2017278192A1 (en) 2018-12-13
MX2018014716A (es) 2019-03-11

Similar Documents

Publication Publication Date Title
AU201616677S (en) Cylindres
DK3468998T3 (en) Anti-tnfrsf25-antistoffer
PL3216505T3 (pl) Mata do zabawy
AU201710580S (en) Bookrack
DK3551631T3 (en) Non-peptid oxytocin-receptoragonister
GB201703128D0 (en) Kraftfahrzeugkarosserie
AU201713059S (en) SUNSHADE - square
GB201619993D0 (en) Flexi-bin
ZA201803338B (en) Degerminator
AU5499P (en) T15-1218 Bituminaria bituminosa
GB201709252D0 (en) Optronische sensorvorrichtung
AU201713060S (en) SUNSHADE - triangle
AU2016376V (en) NinbellaPurple Alyogyne huegelii
AU2016361V (en) JCU8 Desmanthus virgatus
AU2016362V (en) JCU9 Desmanthus pernambucanus
AU2016360V (en) JCU7 Desmanthus leptophyllus
AU2016359V (en) JCU6 Desmanthus bicornutus
GB201620395D0 (en) Clothes-hangers
AU201616673S (en) tallboy
AU2016303V (en) Desse1601 Desmanthus virgatus
GB201617563D0 (en) Tri-bomb
GB201617214D0 (en) V-chat
GB201615942D0 (en) NowMoji
GB201614669D0 (en) Bulgeomers
AP2016001138S (en) Chisa kooka